iNKT Cell Gene Expression and Effector Function in Type 1 Diabetes

1 型糖尿病中的 iNKT 细胞基因表达和效应器功能

基本信息

  • 批准号:
    7185718
  • 负责人:
  • 金额:
    $ 33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-12-01 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

CD1d-restricted T cells (or "iNKT cells") have been reported to regulate an extremely diverse set of immunologic responses and diseases. Dysfunction including cytokine secretion by these T cells is clearly correlated with the development of autoimmunity, and in particular autoimmune type 1 diabetes. Despite the importance of CDId-restricted T cells in this disease, the question of how these T cells function normally and the exact nature of the disease-associated defects remains unclear. In this regard, potential regulatory functions that would be predicted to have significant impact on type 1 diabetes include recently described critical interactions of CDId-restricted T cells with dendritic cells (DC; the focus of Project 2) and the activation-induced secretion of regulatory cytokines. Recent work has demonstrated that in normal human volunteers, the CD4+ CDId-restricted subset preferentially secrete regulatory cytokines, whereas the CD4- (or "DM") subset were strongly biased towards the secretion of Th1-related cytokines and expressed greater levels of proteins with cytotoxic function. We have observed that individuals at risk for type 1 diabetes have a significant bias towards the DN subset. Perhaps more importantly, CD4+ iNKT cells preferentially express FOXP3 (the focus of Project 3) and secrete an as of yet to be identified factor that induces myeloid DC differentiation. Interestingly, the expression of FOXP3 is dependent on IL-2 and CD25, both of which are candidate type 1 diabetes susceptibility alleles. Thus, CD4+ CD1 d-restricted T cells might serve to prevent progression to diabetes by controlling DC maturation and effector T cells while DN CDId-restricted T cells might promote pro-inflammatory responses. In this proposal, we plan to investigate with Projects 2 and 3, the mechanism by which CD4+ and DN iNKT cells interact and regulate T effector cells and APC. To that end, our proposal will specifically test the hypothesis that CD4+ iNKT cells are a unique class of regulatory T cells and may serve to prevent progression to autoimmune type 1 diabetes, while DN iNKT cells play a more pathogenic role. This hypothesis predicts that reduced activity of the CD4+ iNKT cell subset compared to that of the DN subset (which could result from a selective defect in CD4+ functions, or an alteration in DN vs. CD4+ proportion), could in some cases be associated with progression to type 1 diabetes. This hypothesis will be tested by performance of two specific aims involving: 1) Analyses of iNKT frequency and function, and 2) Characterization of DC differentiation factor(s) secreted by CD4+ iNKT cells. Together with Projects 2 and 3, the successful completion of these studies could lead to an improved understanding of the mechanisms underlying the autoimmune activity that that results in type 1 diabetes as well as the identification of novel factors important to immune regulation.
据报道,CD1d限制性T细胞(或称iNKT细胞)调节一组极其不同的 免疫反应和疾病。这些T细胞的功能障碍包括分泌细胞因子显然是 与自身免疫性疾病,特别是自身免疫性1型糖尿病的发展有关。尽管 CDID限制性T细胞在本病中的重要性,这些T细胞如何正常发挥作用以及 与疾病相关的缺陷的确切性质尚不清楚。在这方面,潜在的监管 预测会对1型糖尿病产生重大影响的功能包括最近描述的 CDID限制性T细胞与树突状细胞(DC,项目2的焦点)的关键相互作用 激活诱导调节性细胞因子的分泌。最近的研究表明,在正常的人类中 在志愿者中,受CD4+CDID限制的亚群优先分泌调节性细胞因子,而CD4-CDID限制的亚群 (或“DM”)亚群强烈偏向于Th1相关细胞因子的分泌,并表达更多 具有细胞毒功能的蛋白质水平。我们观察到,有1型糖尿病风险的人有 对目录号码子集的显著偏向。也许更重要的是,CD4+iNKT细胞优先表达 Foxp3(项目3的焦点),并分泌一种尚未确定的诱导髓系DC的因子 差异化。有趣的是,FOXP3的表达依赖于IL-2和CD25,两者都是 候选1型糖尿病易感等位基因。因此,CD4+CD1d限制性T细胞可能起到预防 通过控制DC成熟和效应T细胞进展为糖尿病,而DNCDID限制T细胞 可能会促进促炎反应。在这项提案中,我们计划与项目2和3一起调查 CD4+和dN iNKT细胞相互作用和调节T效应细胞和APC的机制。为此, 我们的建议将专门检验这一假设,即CD4+iNKT细胞是一种独特的调节性T细胞 可能有助于防止进展为自身免疫性1型糖尿病,而糖尿病肾病iNKT细胞则发挥更大的作用 致病作用。这一假设预测,与CD+iNKT细胞亚群相比, 糖尿病肾病亚集(这可能是由于CD4+功能的选择性缺陷,或糖尿病肾病与 在某些情况下,可能与进展为1型糖尿病有关。这一假设 将通过两个具体目标的表现进行测试,包括:1)分析iNKT的频率和功能, 2)CD_4~+iNKT细胞分泌的DC分化因子(S)的鉴定。与项目2一起 3、这些研究的成功完成可能会提高人们对 导致1型糖尿病的自身免疫活动的潜在机制以及 识别对免疫调节重要的新因素。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

S. Brian BRIAN Wilson其他文献

S. Brian BRIAN Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('S. Brian BRIAN Wilson', 18)}}的其他基金

iNKT Cell Gene Expression and Effector Function in Type 1 Diabetes
1 型糖尿病中的 iNKT 细胞基因表达和效应器功能
  • 批准号:
    8319518
  • 财政年份:
    2011
  • 资助金额:
    $ 33万
  • 项目类别:
iNKT Cell Gene Expression and Effector Function in Type 1 Diabetes
1 型糖尿病中的 iNKT 细胞基因表达和效应器功能
  • 批准号:
    7681498
  • 财政年份:
    2008
  • 资助金额:
    $ 33万
  • 项目类别:
Regulation of Phosphoprotein Signalling in CD4+ and DN iNKT Cell Subsets
CD4 和 DN iNKT 细胞亚群中磷蛋白信号传导的调节
  • 批准号:
    7237981
  • 财政年份:
    2007
  • 资助金额:
    $ 33万
  • 项目类别:
Regulation of Phosphoprotein Signalling in CD4+ and DN iNKT Cell Subsets
CD4 和 DN iNKT 细胞亚群中磷蛋白信号传导的调节
  • 批准号:
    7500313
  • 财政年份:
    2007
  • 资助金额:
    $ 33万
  • 项目类别:
Role of CD4+ and DN CD1d-Restricted T Cells in Type 1 Diabetes
CD4 和 DN CD1d 限制性 T 细胞在 1 型糖尿病中的作用
  • 批准号:
    7524017
  • 财政年份:
    2007
  • 资助金额:
    $ 33万
  • 项目类别:
REGULATION OF IL4 SECRETION BY INVARIANT T CELLS
恒定 T 细胞对 IL4 分泌的调节
  • 批准号:
    6510960
  • 财政年份:
    1999
  • 资助金额:
    $ 33万
  • 项目类别:
REGULATION OF IL4 SECRETION BY INVARIANT T CELLS
恒定 T 细胞对 IL4 分泌的调节
  • 批准号:
    6374112
  • 财政年份:
    1999
  • 资助金额:
    $ 33万
  • 项目类别:
Regulation of iNKT and APC Interactions
iNKT 和 APC 相互作用的调节
  • 批准号:
    7558522
  • 财政年份:
    1999
  • 资助金额:
    $ 33万
  • 项目类别:
REGULATION OF IL4 SECRETION BY INVARIANT T CELLS
恒定 T 细胞对 IL4 分泌的调节
  • 批准号:
    6171071
  • 财政年份:
    1999
  • 资助金额:
    $ 33万
  • 项目类别:
Regulation of iNKT and APC Interactions
iNKT 和 APC 相互作用的调节
  • 批准号:
    7162518
  • 财政年份:
    1999
  • 资助金额:
    $ 33万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 33万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 33万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 33万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 33万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 33万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 33万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 33万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 33万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 33万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了